Literature DB >> 33687995

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Peter Garred1, Andrea J Tenner1, Tom E Mollnes2.   

Abstract

The complement system was discovered at the end of the 19th century as a heat-labile plasma component that "complemented" the antibodies in killing microbes, hence the name "complement." Complement is also part of the innate immune system, protecting the host by recognition of pathogen-associated molecular patterns. However, complement is multifunctional far beyond infectious defense. It contributes to organ development, such as sculpting neuron synapses, promoting tissue regeneration and repair, and rapidly engaging and synergizing with a number of processes, including hemostasis leading to thromboinflammation. Complement is a double-edged sword. Although it usually protects the host, it may cause tissue damage when dysregulated or overactivated, such as in the systemic inflammatory reaction seen in trauma and sepsis and severe coronavirus disease 2019 (COVID-19). Damage-associated molecular patterns generated during ischemia-reperfusion injuries (myocardial infarction, stroke, and transplant dysfunction) and in chronic neurologic and rheumatic disease activate complement, thereby increasing damaging inflammation. Despite the long list of diseases with potential for ameliorating complement modulation, only a few rare diseases are approved for clinical treatment targeting complement. Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorders. Rare diseases, unfortunately, preclude robust clinical trials. The increasing evidence for complement as a pathogenetic driver in many more common diseases suggests an opportunity for future complement therapy, which, however, requires robust clinical trials; one ongoing example is COVID-19 disease. The current review aims to discuss complement in disease pathogenesis and discuss future pharmacological strategies to treat these diseases with complement-targeted therapies. SIGNIFICANCE STATEMENT: The complement system is the host's defense friend by protecting it from invading pathogens, promoting tissue repair, and maintaining homeostasis. Complement is a double-edged sword, since when dysregulated or overactivated it becomes the host's enemy, leading to tissue damage, organ failure, and, in worst case, death. A number of acute and chronic diseases are candidates for pharmacological treatment to avoid complement-dependent damage, ranging from the well established treatment for rare diseases to possible future treatment of large patient groups like the pandemic coronavirus disease 2019.
Copyright © 2021 by The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33687995      PMCID: PMC7956994          DOI: 10.1124/pharmrev.120.000072

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  420 in total

Review 1.  New insights into the role of ficolins in the lectin pathway of innate immunity.

Authors:  Yuichi Endo; Misao Matsushita; Teizo Fujita
Journal:  Int Rev Cell Mol Biol       Date:  2015-02-20       Impact factor: 6.813

Review 2.  Monoclonal antibody therapeutics: history and future.

Authors:  Nicholas A P S Buss; Simon J Henderson; Mary McFarlane; Jacintha M Shenton; Lolke de Haan
Journal:  Curr Opin Pharmacol       Date:  2012-08-21       Impact factor: 5.547

3.  Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation.

Authors:  Déla Golshayan; Agnieszka Wójtowicz; Stéphanie Bibert; Nitisha Pyndiah; Oriol Manuel; Isabelle Binet; Leo H Buhler; Uyen Huynh-Do; Thomas Mueller; Jürg Steiger; Manuel Pascual; Pascal Meylan; Pierre-Yves Bochud
Journal:  Kidney Int       Date:  2016-02-03       Impact factor: 10.612

Review 4.  Complement inhibition in C3 glomerulopathy.

Authors:  Carla M Nester; Richard J H Smith
Journal:  Semin Immunol       Date:  2016-07-09       Impact factor: 11.130

Review 5.  Complement deficiency states and associated infections.

Authors:  Lillemor Skattum; Marcel van Deuren; Tom van der Poll; Lennart Truedsson
Journal:  Mol Immunol       Date:  2011-05-31       Impact factor: 4.407

Review 6.  Complement in immune and inflammatory disorders: pathophysiological mechanisms.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

7.  Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation.

Authors:  Hansen Lui; Jiasheng Zhang; Stefanie R Makinson; Michelle K Cahill; Kevin W Kelley; Hsin-Yi Huang; Yulei Shang; Michael C Oldham; Lauren Herl Martens; Fuying Gao; Giovanni Coppola; Steven A Sloan; Christine L Hsieh; Charles C Kim; Eileen H Bigio; Sandra Weintraub; Marek-Marsel Mesulam; Rosa Rademakers; Ian R Mackenzie; William W Seeley; Anna Karydas; Bruce L Miller; Barbara Borroni; Roberta Ghidoni; Robert V Farese; Jeanne T Paz; Ben A Barres; Eric J Huang
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

8.  Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo.

Authors:  Natalie J Hepburn; Jayne L Chamberlain-Banoub; Anwen S Williams; B Paul Morgan; Claire L Harris
Journal:  Mol Immunol       Date:  2007-07-24       Impact factor: 4.407

9.  Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis.

Authors:  Silvia De-la-Iglesia; Hugo Luzardo; Angelina Lemes; Melissa Torres; Maria Teresa Gómez-Casares; Naylen Cruz; Teresa Molero
Journal:  Hematol Rep       Date:  2016-09-30

10.  Should MASP-2 Deficiency Be Considered a Primary Immunodeficiency? Relevance of the Lectin Pathway.

Authors:  M Isabel García-Laorden; Elisa Hernández-Brito; Carmen Muñoz-Almagro; Svetlana Pavlovic-Nesic; Iñigo Rúa-Figueroa; M Luisa Briones; Olga Rajas; Luis Borderías; Antoni Payeras; Leonardo Lorente; Jordi Freixinet; Jose Ferreres; Ignacio Obando; Nereida González-Quevedo; Felipe Rodríguez de Castro; Jordi Solé-Violán; Carlos Rodríguez-Gallego
Journal:  J Clin Immunol       Date:  2019-12-11       Impact factor: 8.317

View more
  21 in total

Review 1.  The yin and the yang of early classical pathway complement disorders.

Authors:  Kathleen E Sullivan
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 2.  Compstatins: the dawn of clinical C3-targeted complement inhibition.

Authors:  Christina Lamers; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Trends Pharmacol Sci       Date:  2022-01-25       Impact factor: 17.638

3.  The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure.

Authors:  Margrethe Flesvig Holt; Annika E Michelsen; Negar Shahini; Elisabeth Bjørkelund; Christina Holt Bendz; Richard J Massey; Camilla Schjalm; Bente Halvorsen; Kaspar Broch; Thor Ueland; Lars Gullestad; Per H Nilsson; Pål Aukrust; Tom Eirik Mollnes; Mieke C Louwe
Journal:  Front Immunol       Date:  2021-12-24       Impact factor: 7.561

Review 4.  The Role of Complement in Synaptic Pruning and Neurodegeneration.

Authors:  Angela Gomez-Arboledas; Munjal M Acharya; Andrea J Tenner
Journal:  Immunotargets Ther       Date:  2021-09-24

5.  Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival.

Authors:  Bartlomiej J Witczak; Søren E Pischke; Anna V Reisæter; Karsten Midtvedt; Judith K Ludviksen; Kristian Heldal; Trond Jenssen; Anders Hartmann; Anders Åsberg; Tom E Mollnes
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

6.  Serum C1q Levels Have Prognostic Value for Sepsis and are Related to the Severity of Sepsis and Organ Damage.

Authors:  Huan Li; Juanjuan Chen; Yuanhui Hu; Xin Cai; Dongling Tang; Pingan Zhang
Journal:  J Inflamm Res       Date:  2021-09-10

Review 7.  Expanding Horizons in Complement Analysis and Quality Control.

Authors:  Ashley Frazer-Abel; Michael Kirschfink; Zoltán Prohászka
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

8.  Human Amnion-Derived Mesenchymal Stromal Cells: A New Potential Treatment for Carbapenem-Resistant Enterobacterales in Decompensated Cirrhosis.

Authors:  Mariangela Pampalone; Giampiero Vitale; Salvatore Gruttadauria; Giandomenico Amico; Gioacchin Iannolo; Bruno Douradinha; Alessandra Mularoni; Pier Giulio Conaldi; Giada Pietrosi
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

Review 9.  Complement Inhibition and COVID-19: The Story so Far.

Authors:  Sofiane Fodil; Djillali Annane
Journal:  Immunotargets Ther       Date:  2021-07-26

Review 10.  Complement and Coagulation System Crosstalk in Synaptic and Neural Conduction in the Central and Peripheral Nervous Systems.

Authors:  Shani Berkowitz; Joab Chapman; Amir Dori; Shany Guly Gofrit; Nicola Maggio; Efrat Shavit-Stein
Journal:  Biomedicines       Date:  2021-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.